Clinical Trial Update: Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial of lanreotide with telotristat ethyl or placebo for first-line treatment in advanced well-differentiated small intestinal neuroendocrine tumors wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Heart Disease
• Small Intestine Neuroendocrine Tumor

Drugs mentioned

• Lanreotide (lanreotide)
• Telotristat Ethyl (telotristat ethyl)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Small Intestinal NET, Carcinoid Heart Disease | Phase 3 | Status: WITHDRAWN